Clay Siegall has achieved much success in cancer research. Over the years, he has been researching about targeted cancer therapy. Clay is the proprietor of Seattle Genetics, a biotechnology company. Under his leadership, Seattle Genetics has succeeded in developing innovative cancer therapies. Clay opted to focus on cancer research after his father was diagnosed with cancer. The scientist watched his father undergo excruciating pain, especially when he went for his chemotherapy sessions. He realized the need to research for better treatments that prolong the lives of cancer patients without subjecting them to much pain. Clay enhances the profits of Seattle Genetics through partnerships with other companies to sell their drugs or advance their technology. They also have a dedicated team of sales experts who help in closing lucrative deals. Clay Siegall believes that hard work is the only way to success. He posits that other factors, including IQ are secondary.
About Dr. Clay B. Siegall
Clay B. Siegall holds a B.S. in zoology from the esteemed University of Maryland and a PhD in Genetics from the celebrated George Washington University. Seattle Genetics has grown from a small startup with few researchers to a recognized authority in cancer research. Siegall serves as the president, chief executive officer and chairman of the board of Seattle Genetics. Owing to his extensive skills in cancer research and leadership abilities, Seattle Genetics has developed a series of cancer therapies. Their first therapy was the antibody-drug conjugate (ADCs), ADCETRIS. ADCETRIS was approved by FDA in 2011. It is sold in over 65 countries. Siegall seeks to ensure that the drug is approved in more countries and prioritized in cancer treatment.
Seattle Genetics has also entered into multiple partnerships for its ADC technology. To date, these partnerships have generated over $350 million. In addition, over 20 ADCs in clinical trials in both internal and collaborator programs are using Seattle Genetics’ technology. Previously, he worked for Bristol-Myers Squibb Pharmaceutical Research Institute and the National Institutes of Health. He serves on the boards of Washington Roundtable, Alder BioPharmaceuticals, and Ultragenyx. Clay has authored over 70 publications and holds 15 patents. His excellent performance in biotechnology has earned him numerous recognition, including the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year. In 2013, Clay Siegall was named the University of Maryland Alumnus of the Year for Computer, Math and Natural Science.